Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Natural Killer/T-cell Lymphoma × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 800 Lymphoma, Non-Hodgkin 611 Leukemia, Lymphocytic, Chronic, B-Cell 587 Lymphoma, Large B-Cell, Diffuse 547 Precursor Cell Lymphoblastic Leukemia-Lymphoma 530 Lymphoma, Follicular 456 Hodgkin Disease 396 Lymphoma, Mantle-Cell 378 Leukemia 367 Burkitt Lymphoma 257 Lymphoma, B-Cell, Marginal Zone 255 Recurrence 251 Leukemia, Myeloid, Acute 241 Multiple Myeloma 220 Myelodysplastic Syndromes 209 Waldenstrom Macroglobulinemia 168 Lymphoma, B-Cell 159 Lymphoma, Large-Cell, Immunoblastic 139 Lymphoma, T-Cell, Cutaneous 130 Lymphoma, T-Cell, Peripheral 110 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 109 Mycosis Fungoides 105 Lymphoma, Large-Cell, Anaplastic 98 Myeloproliferative Disorders 97 Dendritic Cell Sarcoma, Interdigitating 94 Sezary Syndrome 85 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 85 Lymphoma, Extranodal NK-T-Cell 82 Hematologic Neoplasms 82 Neoplasms 81

Interventions

isatuximab 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04763616 2021-09-24

ICING

Samsung Medical Center

Phase 2 Recruiting

Natural Killer/T-cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡